These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33093601)

  • 21. PBP2a substitutions linked to ceftaroline resistance in MRSA isolates from the UK.
    Harrison EM; Ba X; Blane B; Ellington MJ; Loeffler A; Hill RL; Holmes MA; Peacock SJ
    J Antimicrob Chemother; 2016 Jan; 71(1):268-9. PubMed ID: 26462986
    [No Abstract]   [Full Text] [Related]  

  • 22. Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance.
    Greninger AL; Chatterjee SS; Chan LC; Hamilton SM; Chambers HF; Chiu CY
    PLoS One; 2016; 11(2):e0149541. PubMed ID: 26890675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs.
    Lahiri SD; Alm RA
    J Antimicrob Chemother; 2016 Nov; 71(11):3050-3057. PubMed ID: 27494915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency of small-colony variants and antimicrobial susceptibility of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients.
    Suwantarat N; Rubin M; Bryan L; Tekle T; Boyle MP; Carroll KC; Jennings MT
    Diagn Microbiol Infect Dis; 2018 Apr; 90(4):296-299. PubMed ID: 29343421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftaroline.
    Lahiri SD; Alm RA
    J Antimicrob Chemother; 2016 Jan; 71(1):34-40. PubMed ID: 26483514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of ceftaroline against methicillin-resistant and methicillin-susceptible Staphylococcus aureus clinical isolates from a tertiary hospital in Greece.
    Tychala A; Protonotariou E; Meletis G; Tsoha A; Mantzana P; Vasilaki O; Kagkalou G; Skoura L
    New Microbiol; 2021 Apr; 44(2):125-128. PubMed ID: 34151995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients.
    Hill RL; Kearns AM; Nash J; North SE; Pike R; Newson T; Woodford N; Calver R; Livermore DM
    J Antimicrob Chemother; 2010 Mar; 65(3):442-5. PubMed ID: 20089543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers.
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    Surg Infect (Larchmt); 2016 Aug; 17(4):443-7. PubMed ID: 26990170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [In vitro activity of ceftaroline to MRSA isolates: a multicenter study].
    Mengeloğlu FZ; Taş T; Koçoğlu E; Copur Çiçek A; Yanık K; Güneş H; Ciftci IH; Durmaz S; Bucak O; Güçkan R; Terzi HA; Yavuz MZ
    Mikrobiyol Bul; 2013 Oct; 47(4):677-83. PubMed ID: 24237436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia.
    Abbott IJ; Jenney AW; Jeremiah CJ; Mirčeta M; Kandiah JP; Holt DC; Tong SY; Spelman DW
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7837-41. PubMed ID: 26392488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-level ceftaroline resistance in a paediatric patient with invasive methicillin-resistant Staphylococcus aureus infection without previous ceftaroline exposure.
    Ferguson CL; Cowart MC; Jordan-Villegas A; Laham F
    J Clin Pharm Ther; 2021 Apr; 46(2):524-527. PubMed ID: 33236793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology.
    Zhang H; Xiao M; Kong F; O'Sullivan MV; Mao LL; Zhao HR; Zhao Y; Wang H; Xu YC
    Int J Antimicrob Agents; 2015 Apr; 45(4):347-50. PubMed ID: 25649348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation.
    McNeil JC; Sommer LM; Vallejo JG; Hulten KG; Kaplan SL; Flores AR
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0074522. PubMed ID: 36165630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates.
    Sader HS; Rhomberg PR; Doyle TB; Flamm RK; Mendes RE
    J Clin Microbiol; 2018 Dec; 56(12):. PubMed ID: 30257898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the antibacterial activity of ceftaroline against clinical isolates of methicillin-susceptible and- resistant Staphylococcus aureus in Kuwait hospitals.
    Alfouzan W; Boswihi SS; Dhar R; Udo E
    J Infect Public Health; 2020 Oct; 13(10):1589-1591. PubMed ID: 32859552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections.
    Urbán E; Stone GG
    Clin Microbiol Infect; 2019 Nov; 25(11):1429.e1-1429.e4. PubMed ID: 30980925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
    Sader HS; Fritsche TR; Jones RN
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1153-5. PubMed ID: 18180353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftaroline vs vancomycin for the treatment of acute pulmonary exacerbations in pediatric patients with cystic fibrosis.
    Branstetter J; Searcy H; Benner K; Yarbrough A; Crowder C; Troxler B
    Pediatr Pulmonol; 2020 Dec; 55(12):3337-3342. PubMed ID: 32803907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.
    Fusco NM; Toussaint KA; Prescott WA
    Ann Pharmacother; 2015 Apr; 49(4):458-68. PubMed ID: 25583881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.